We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
- Authors
Robbins, Paul F; Morgan, Richard A; Feldman, Steven A; Yang, James C; Sherry, Richard M; Dudley, Mark E; Wunderlich, John R; Nahvi, Azam V; Helman, Lee J; Mackall, Crystal L; Kammula, Udai S; Hughes, Marybeth S; Restifo, Nicholas P; Raffeld, Mark; Lee, Chyi-Chia Richard; Levy, Catherine L; Li, Yong F; El-Gamil, Mona; Schwarz, Susan L; Laurencot, Carolyn; Rosenberg, Steven A
- Abstract
Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 cancer/testis antigen, which is expressed in 80% of patients with synovial cell sarcoma and approximately 25% of patients with melanoma and common epithelial tumors, represents an attractive target for immune-based therapies. The current trial was carried out to evaluate the ability of adoptively transferred autologous T cells transduced with a T-cell receptor (TCR) directed against NY-ESO-1 to mediate tumor regression in patients with metastatic melanoma and synovial cell sarcoma.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 7, p917
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.32.2537